Companies › JT International
1 active drug program in 29 registered trials: 16 Phase 4, 5 Phase 3, 5 Phase 2, 3 Phase 1; Infectious disease, Oncology, Other, Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nicotine Neuronal acetylcholine receptor; alpha4/beta2 agonist | CHRNB2, CHRNA4 | Phase 1 | Smoking Behaviors; Nicotine Dependence; Tobacco Use Disorder; Tobacco … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07476144 | Nicotine | Phase 1 | Smoking Behaviors | Other | Jul 2026 |
| NCT05233228 | Nicotine | Phase 2 | Cigarette Smoking | Other | Aug 2026 |
| NCT04176172 | Nicotine | Phase 3 | HIV/AIDS | Infectious disease | Nov 2026 |
| NCT05515354 | Nicotine | Phase 4 | Nicotine Dependence | Psychiatry | Dec 2026 |
| NCT07585006 | Nicotine | Phase 1 | Tobacco-Related Carcinoma | Oncology | Dec 2026 |
| NCT05722561 | Nicotine | Phase 2 | Opioid Use Disorder | Psychiatry | Mar 2027 |
| NCT05587361 | Nicotine | Phase 4 | Tobacco Use Disorder | Psychiatry | Mar 2027 |
| NCT06832085 | Nicotine | Phase 4 | Tobacco | Other | Apr 2027 |
| NCT06832098 | Nicotine | Phase 3 | Vaping Cessation | Other | Apr 2027 |
| NCT05513872 | Nicotine | Phase 1 | Tobacco Use | Psychiatry | Aug 2027 |
| NCT03315910 | Nicotine | Phase 4 | Smoking Cessation | Other | Oct 2027 |
| NCT03315910 | Nicotine | Phase 4 | Smoking Cessation | Other | Oct 2027 |
| NCT05723588 | Nicotine | Phase 2 | Tobacco Use Disorder | Psychiatry | Nov 2027 |
| NCT07503925 | Nicotine | Phase 4 | Tobacco-Related Carcinoma | Oncology | Dec 2027 |
| NCT07503925 | Nicotine | Phase 4 | Tobacco-Related Carcinoma | Oncology | Dec 2027 |
| NCT06315881 | Nicotine | Phase 2 | Tobacco-Related Carcinoma | Oncology | Jan 2028 |
| NCT06598397 | Nicotine | Phase 4 | Human Immunodeficiency Virus (HIV) | Infectious disease | Jun 2028 |
| NCT06474299 | Nicotine | Phase 4 | Smoking Cessation | Other | Jul 2028 |
| NCT06630728 | Nicotine | Phase 4 | Smoking (Tobacco) Addiction | Psychiatry | Dec 2028 |
| NCT06630728 | Nicotine | Phase 4 | Smoking (Tobacco) Addiction | Psychiatry | Dec 2028 |
| NCT06595459 | Nicotine | Phase 4 | Smoker | Other | Jan 2029 |
| NCT06595459 | Nicotine | Phase 4 | Smoker | Other | Jan 2029 |
| NCT07099638 | Nicotine | Phase 2 | Smoking Cessation | Other | Jun 2029 |
| NCT07095205 | Nicotine | Phase 4 | Major Depressive Disorder (MDD) | Psychiatry | Sep 2029 |
| NCT05154669 | Nicotine | Phase 3 | Smoking | Other | Dec 2029 |
| NCT05154669 | Nicotine | Phase 3 | Smoking | Other | Dec 2029 |
| NCT05154669 | Nicotine | Phase 3 | Smoking | Other | Dec 2029 |
| NCT07419425 | Nicotine | Phase 4 | Smoking Cessation | Other | Jan 2030 |
| NCT07089901 | Nicotine | Phase 4 | Smoking | Other | Mar 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.